ABBV-6628

PreclinicalSmall molecule

AbbVie

ABBV-6628 is one of 13 small molecule programs targeting Geographic Atrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Geographic AtrophyRecruiting

Geographic AtrophyPreclinical

Recruiting

Competition

Competitive Landscape

18 competitors in Geographic Atrophy

#DrugCompanyPhaseTrials

Lucentis

Roche

Approved

2 2

Eylea

Regeneron

Approved

1 3

Izervay

Astellas

Approved

3 4

Farxiga

AstraZeneca

Phase 2

1 5

Tecfidera

Biogen

Phase 2

1 6

Tinlarebant

BBelite Bio, Inc

Phase 3

1 7

Vonaprument

AAnnexon, Inc.

Phase 3

2 8

Opregen

Roche

Phase 2

1 9

JNJ-81201887

Johnson & Johnson

Phase 2

1 10

BS01

BBionic Sight LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

Geographic Atrophy

NCT07160179

Clinical

Trials by Indication[1]

Geographic Atrophy1 trial

Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT07160179·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABBV-6628. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABBV-6628 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABBV-6628. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AbbVie

ABBV-6628

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Geographic Atrophy1 trial

References

Drug Info

Quick Facts

Related News